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Abstract
Each year thousands of patients are at risk of cerebral ischemic injury, due to iatrogenic responses 
to surgical procedures. Prophylactic treatment of these patients as standard care could minimize 
potential neurological complications. We have shown that protection of brain tissue, in a non-
human primate model of cerebral ischemic injury, is possible through pharmacological 
preconditioning using the immune activator D192935. We postulate that preconditioning with 
D192935 results in neuroprotective reprogramming that is evident in the brain following 
experimentally induced cerebral ischemia. We performed quantitative proteomic analysis of 
cerebral spinal fluid (CSF) collected post-stroke from our previously published efficacy study to 
determine whether CSF protein profiles correlated with induced protection. Four groups of 
animals were examined: naïve animals (no treatment or stroke); animals treated with vehicle prior 
to stroke; D192935 treated and stroked animals, further delineated into two groups, ones that were 
protected (small infarcts) and those that were not protected (large infarcts). We found that distinct 
protein clusters defined the protected and non-protected animal groups, with a 16-member cluster 
of proteins induced exclusively in D192935 protected animals. Seventy percent of the proteins 
induced in the protected animals have functions that would enhance neuroprotection and tissue 
repair, including several members associated with M2 macrophages, a macrophage phenotype 
shown to contribute to neuroprotection and repair during ischemic injury. These studies highlight 
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the translational importance of CSF biomarkers in defining mechanism and monitoring responses 
to treatment in development of stroke therapeutics.
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Introduction:
Neurological impairments, including ischemic stroke, are a major complication of life-
saving endovascular and cardiac procedures [1,2]. Advances in neuroimaging indicate that 
peri-procedural brain lesions can occur in up to 50% of patients undergoing these treatments 
[3–7]. Prophylactic treatment designed to protect brain tissue in the event of an ischemic 
episode, may be extremely beneficial to these patients. Experimental models of ischemia 
have demonstrated that prophylactic protection of tissue is possible through an induced 
process known as preconditioning, in which exposure to a small dose of an otherwise 
harmful stimulus induces a protective state against a subsequent ischemic event [8]. In 
animal models, protection of multiple tissues (i.e. brain, heart, kidney) has been 
demonstrated using brief ischemia as well as pharmacological induction of mild 
inflammation [9–12]. Transient remote ischemic preconditioning, using a tourniquet 
approach applied to the limbs to induce protection to the heart and kidney is already being 
tested in clinical trials [13–15]. Understanding these endogenous mechanisms of 
preconditioning-induced tissue protection would further translational development of 
potential prophylactic treatments for high-risk patients.
We have previously demonstrated protection against cerebral ischemic injury in murine and 
non-human primate (NHP) experimental models using pharmacological activation of toll-
like receptor 9 (TLR9) to engage the innate immune response [9,16,17]. Extensive studies in 
our mouse model indicate that preconditioning prior to the ischemic insult results in an 
altered brain response to the injury. New genes are induced in the brain that indicate the 
activation of novel neuroprotective pathways that are not evident in the non-protected mouse 
brain [18]. Although we have demonstrated that an activator of TLR9 can provide significant 
protection in our NHP model of cerebral ischemia [9,16], the molecular mechanisms 
associated with protection have not been elucidated. We hypothesize that, similar to the 
mouse, preconditioning of the NHP results in a reprogrammed response to ischemic injury 
that contributes to protection. To explore further the molecular changes that accompany 
preconditioning induced neuroprotection, we have examined cerebral spinal fluid (CSF) 
collected 7-days post occlusion from preconditioned and non-preconditioned NHPs, to 
determine whether preconditioning alters the brain’s response to injury in this higher-order 
species and whether such changes are associated with neuroprotection.
As these studies make use of samples collected from our previous NHP efficacy study, the 
scope of this study was limited to tissue/resources available. Hence, the study was confined 
to examine evidence of a preconditioning induced protective response in CSF collected from 
animals at the time of necropsy (7 days post occlusion). CSF is a repository of protein and 
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has already proven to be an important site for biomarker analysis for many neurological 
disorders, such as Alzheimer’s Disease, multiple sclerosis and stroke [19–23], thus 
providing an ideal medium for assessing potential changes in the brain associated with 
protection. In addition, at this late time point, evidence of a protected response is more likely 
to be manifested in protein differences, rather than transcriptional changes. Herein, we 
performed quantitative proteomics analysis using 10-plexed isobaric tandem mass tag 
(TMT-10) labeling [24] and off-line two-dimensional liquid chromatography coupled to 
tandem mass spectrometry (2D-LC-MS/MS), to assess the proteomic changes in the CSF.
Methods:
Cerebral Spinal Fluid Samples.
CSF samples were collected during a previously published study demonstrating the efficacy 
of a TLR9 agonist (D192935) to reduce cerebral ischemic injury in the non-human primate 
[16]. In brief, adult male rhesus macaques were treated with D192935 or vehicle 3 days 
prior to 60minute middle cerebral artery and anterior cerebral artery occlusion (MACAO). 
CSF was collected 7 days following MACAO (at necropsy) immediately centrifuged and 
clarified samples stored at −80C for further analysis. Four groups were compared: 1) Drug 
protected (DP)- D192935 treated followed by MACAO (small infarcts: group mean 1.36 +/
− 1.2% of whole brain Fig. 1; n=5), 2) Drug not protected (DNP)- D192935 treated followed 
by MACAO (large infarcts: group mean 6.35 +/− 1.2% of whole brain Fig. 1; n=5), 3) 
Control (CNTL)- vehicle treated followed by MACAO (group mean 8.72 +/− 1.1% of whole 
brain Fig. 1; n=5), and 4) Naïve- no treatment or surgery (n=4).
Digestion of CSF samples.
Approximately 500 μL of each CSF sample was concentrated to ~100 μL using a Millipore 
Amicon Ultra-15 3000 MWCO filter (Fisher Scientific). Solid urea and 100 mM 
dithiothreitol were added to each sample to a final concentration of 8 M and 10 mM, 
respectively, and the samples were incubated at 37 °C for 1 hour to denature and reduce the 
proteins, after which the samples were alkylated with 40 mM iodoacetamide for 1 hour in 
the dark at 37 °C. The samples were diluted 10x with 50 mM NH4HCO3, 10 mM CaCl2, and 
digested with sequencing grade modified trypsin (Promega) for 3 hour at 37 °C, using 1:50 
trypsin-to-protein ratio. The samples were acidified with 10% trifluoroacetic acid and 
centrifuged at 14,000g before being desalted by C18 solid phase extraction (Supelco) and 
dried. Final peptide concentration was determined with BCA assay (Pierce).
TMT-10 labelling and fractionation.
The TMT labelling was performed per manufacturer’s instructions. A pooled reference was 
first created with equal contribution from each sample. This pooled reference sample, and 
each individual sample were dried and dissolved in triethylammonium bicarbonate, before 
the TMT reagent prepared in anhydrous acetonitrile was added. The TMT-10 labelling 
scheme is shown in Supplementary Table 1. The reaction was incubated at room temperature 
for 90 min prior to termination with 5% hydroxylamine. Samples with different TMT 
labelling in the same TMT-10 experiment were combined, acidified and desalted on C18 
solid phase extraction column, followed by basic pH reversed-phase LC (bRPLC) 
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fractionation and concatenation [25]. Mobile phases were: A) 10 mM ammonium formate, 
pH 10 and B) 10 mM ammonium formate, 90% acetonitrile, pH 10. Sample separation was 
carried out at a flow rate of 0.5 mL/min using the following gradient (minute: B%): 0:0, 
35:0, 41:10, 127:30, 137:42.5, 142:55, 147:100, 148:0 and 178:0. Fractions were collected 
from 48 to 164 min with equal intervals of 1.2 min and the fractions were concatenated into 
24 final fractions [25].
LC-MS/MS analysis.
The LC system was custom built using two Agilent 1200 nanoflow pumps, one Agilent 1200 
capillary pump (Agilent Technologies) and a PAL autosampler (Leap Technologies). 
Reversed-phase columns were prepared in-house by slurry packing 3-μm Jupiter C18 
(Phenomenex) into 40 cm × 360 μm o.d. × 75 μm i.d. fused silica column (Polymicro 
Technologies Inc.) using a 3-mm sol-gel frit for media retention. Trapping columns were 
prepared similarly by slurry packing 5-μm Jupiter C18 into a 4-cm length of 150 μm i.d. 
fused silica and fritted on both ends. Mobile phases consisted of 0.1% formic acid in water 
(A) and 0.1% formic acid in acetonitrile (B) operated at 300 nL/min with a gradient profile 
as follows (minutes: %B); 0:5, 2:8, 20:12, 75:35, 97:60, 100:85. Samples were injected and 
analyzed using the capillary RPLC system coupled online to a Q Exactive Plus Orbitrap 
mass spectrometer (Thermo Scientific). Full MS spectra (400–2,000 m/z) were acquired 
with a resolution of 35,000. Top-10 most intensive precursor ions were selected for MS/MS 
using higher energy collision dissociation (HCD) with a normalized collision energy of 
30%, and the product ions were detected in the Orbitrap with a resolution of 35,000.
Protein Identification and Quantification.
The MS raw data were searched against the UniProt macaque protein database using MS-GF
+ [26]. The searching parameters are: precursor ion mass tolerance (±10 ppm), partial tryptic 
specificity, dynamic oxidation of Met (15.9949 Da), static alkylation on Cys (57.0215 Da), 
and static TMT labelling on the N-terminal and Lys (229.1629 Da). The search results were 
filtered to obtain a false identification rate of <1% at peptide level.
The intensities of all ten TMT reporter ions were extracted using MASIC software [27]. The 
reporter ion intensities from different scans and/or different fractions corresponding to the 
same protein were summed. Relative protein abundance was then calculated as the ratio of 
sample abundance to abundance of the pooled reference (i.e., sample/reference) and log2 
transformed to obtain final relative expression values. This allows comparison of relative 
protein abundances across the entire sample set with minimum variation from each TMT-10 
experiment. The strategy of using a common “internal” reference for merging different 
multiplexed experiments in isobaric labelling analysis has been demonstrated recently as a 
highly effective and reliable way for large-scale quantitative proteomics analysis [28,29].
Statistical and Bioinformatics Analyses.
To correct for potential differences in sample loading in the same TMT10 experiment, the 
median log2 relative abundance of the proteins present in each sample was computed and re-
centered. Moderated 3-group (CNTL, DP and DNP) ANOVA was performed using the 
limma package [30]. The null hypothesis is no difference between the different sample 
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groups. To correct for multiplicity of hypothesis testing, individual protein values were 
adjusted by converting to q-values using a corresponding R package [31]. Principle 
component analysis (PCA) and unsupervised hierarchical clustering were performed in R. 
Clustering was performed on proteins that were differentially expressed between DNP and 
DP with FDR < 0.2. Distance metric was based on Pearson correlation. Specifically, distance 
= (1 – cor)/2, making a highly positive correlation (cor = 1) have a distance 0 and inversely 
correlated (−1) have a distance 1. The macaque UniProt IDs were linked to human 
orthologues using InParanoid database [32].
Results:
Experimental Groups:
In our previously published efficacy study, we found that the TLR9 agonist, D192935 
provided significant protection when administered via intramuscular injection 3 days prior to 
surgically induced cerebral ischemia [16]. Although significant protection was observed in 
the group of animals treated with D192935, there was a range of infarct sizes noted, that 
suggested that not all animals responded to the treatment equally (range from 0 to 9.2% of 
total brain). Based on the heterogeneity of the NHP population, the variable response was 
anticipated as it has been reported that TLR9 immune responses in humans vary between 
individuals [33–35]. In fact, D192935 is a mixture of 3 oligodeoxynucleotide sequences 
combined to provide the broadest activation between human individuals [16,33]. To 
determine whether key pathways of neuroprotection could be identified in protected animals 
we compared proteomic profiles in the CSF collected 7 days following MACAO from five 
animals that received D192935 and exhibited small infarcts (DP; range 0 to 2.9%, mean 1.36 
+/− 1.2% of total brain; Fig. 1), five animals that received D192935 and failed to be 
protected (DNP; large infarcts; range 4.5% to 8.0%, mean 6.35 +/− 1.2% of total brain; Fig. 
1), and 5 animals treated with vehicle (CNTL; range 7.5% to 10.2%, mean 8.72 +/− 1.1% of 
total brain; Fig. 1) as well as a group of naïve animals (n=4): non-treated and not exposed to 
ischemia.
Proteomic analysis:
The multiplexed TMT-10 labeling method coupled to offline 2D-LC-MS/MS allowed for 
precise quantitative analysis of the individual CSF samples while achieving comprehensive 
proteome coverage. A total of 28641 peptides were identified in the CSF samples 
(Supplementary Table 2), covering 4029 proteins (Supplementary Table 3). Of these proteins 
identified, 2125 had complete data for all 19 samples. PCA analysis using these proteins 
showed complete separation of the DP and DNP groups, and that the DNP group is more 
similar to the CNTL group (Fig. 2). In addition, the naïve and DP groups show a slight 
overlap, but still delineate into distinct groups (Fig. 2). We were able to map 2751 of the 
macaque proteins to human orthologues using the InParanoid database (Supplementary 
Table 4), which were used for further statistical and pathway analyses.
Hierarchical clustering:
Clustering the individual animals based on expression levels of the proteins identified as 
differentially regulated in the CNS by ANOVA (adjusted p value <0.05; Supplementary 
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Table 5), clearly differentiates the naïve and DP (“Minimal Damage” group) form the CNTL 
and DNP (“Damage” group; Fig. 3- point A). Proteins were clustered based on differential 
expression between the DNP and DP (FDR < 0.2), and two clusters were identified (Fig. 3-
Left side dendrogram). The hallmark of the Minimal Damage animal cluster appears to be 
low expression of the proteins associated with the Orange protein cluster. The animals in the 
Damage cluster, have high expression levels of proteins in the Orange cluster suggesting that 
these proteins might be related to the evolution of injury (Supplementary Table 6). The 
Minimal Damage cluster is further delineated by increased expression of proteins in the 
Green cluster, separating all five DP animals from the naïve group (Fig. 3- point B). 
Interestingly, similar to the control non-stroked animals (CNTL) the animals in the Damage 
cluster have low levels of proteins in the Green cluster. The increased expression of the 
proteins in the Green cluster in the DP animal group compared to the other animal groups 
suggests that these proteins may be associated with neuroprotection (Fig. 3- Left side 
dendrogram; Table 1). The delineation of groups by their proteomic expression profiles 
indicates that proteins in the CNS reflect physiological differences between the groups and 
may provide insight into protein profiles involved in injury and neuroprotection/repair.
Proteins in the neuroprotective cluster:
Of the 16 proteins identified in the neuroprotective cluster (Green) six are significantly 
increased compared to naïve animals: Adiponectin (ADIPOQ), Mannose Binding Lectin 2 
(MBL2), Sex hormone-binding globulin (SHBG), Coagulation Factor XIII A chain (F13A1), 
Lysyl oxidase like 1 (LoxL1), and Myosin heavy chain 2 (MYH2) (Fig. 4). In addition, all 
but one, Heparan sulfate 6-O Sulfotransferase 1 (HS6ST1), of the other 10 proteins also 
show a trend towards increased expression compared to naïve animals (Supplemental Fig. 
1). The fact that these proteins are increased compared to naïve animals suggests that they 
may define and/or contribute to a neuroprotective state. Pearson correlation analysis of 
individual animals found that infarct size was negatively correlated with each of the 6 
significantly increased proteins.
Discussion:
We have previously shown that the immune activator D192935, provides significant 
protection against ischemia-reperfusion injury in the NHP [16]. In the studies reported here, 
CSF collected from the original study animals at necropsy was used to determine whether 
proteins in the CSF reflect a change in the response to injury that may highlight mechanisms 
of protection. Our studies show that clustering of animals based on protein expression levels 
in the CSF following ischemic injury delineated the NHPs into those with minimal injury 
and those with significant injury. Of note, two distinct clusters of proteins were identified, 
one cluster being upregulated in the animals with minimal injury (DP) and the other 
increased in the animals with significant injury (DNP and CNTL). Proteins in these clusters 
may represent pathways in the brain associated with neuroprotection and damage 
respectively, highlighting potential targets for further therapeutic development.
Our perspective that CSF could act as a window into the state of the brain is based on the 
fact that CSF circulates through the central nervous system moving molecules throughout 
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the brain and removing metabolic waste, making it an ideal repository for protein regulators 
and indicators of brain function. During stroke, leakage of proteins from the periphery 
occurs through degradation of the blood brain barrier (BBB). Such leakage can contribute to 
the protein profile of the CSF and influence responses directly in the brain. Although we did 
not measure BBB integrity in these studies, BBB leakage likely contributes significantly to 
the proteins identified in the CSF following stroke. In the Damaged animals, BBB 
degradation would be expected to be severe and would allow peripheral proteins to leak into 
the CSF contributing to the orange cluster of proteins which are increased in these animals. 
However, it is noteworthy that proteins in the green cluster are increased in the protected 
animals and not in the damaged animals. This indicates that the proteins detected in the CSF 
are not simply a non-specific influx that occurred due to potential BBB leakage because 
these proteins are not increased in the more severely injured animals. Whether the proteins 
in the green cluster originate in the brain or extravasate from the periphery, their exclusive 
increase in the protected animals suggests they may represent a mechanism of protection 
engaged by D192935 preconditioning.
We found a significant number of proteins increased in the CSF 7 days post the ischemic 
event, indicating that even at this late time point the brain continues to respond to the injury. 
One limitation of our study is that at this late time point the predominant responses are likely 
reparative in nature and that acute protective responses may be missed. Thus, although our 
data does not address a potential role for acute response in the protected animals, it does 
highlight potential pathways that may have been initiated in response to the stroke in the 
protected animals. The proteomic profiles of the CSF proteins define two clusters of proteins 
that differentiate the animal groups, one associated with the protective phenotype while the 
other corresponds to the damage phenotype. Eleven of the 16 proteins identified in the 
neuroprotective cluster have known functions that could contribute to neuroprotection. Four 
of these, adiponectin, F13A1, ORM1/AGP1 and STAB1 are directly associated with type 2 
immunosuppressive macrophages (M2), a cell type that has been shown to be 
neuroprotective in animal models of stroke and in clinical trials (reviewed in [36]). Amantea 
and colleagues found that azithromycin, an immunomodulatory molecule, reduced ischemic 
injury in a mouse cerebral ischemia model through the polarization of macrophages to an 
M2 phenotype [37]. In humans, a phase I/II clinical trial found that stroke patients treated 
with autologous M2 macrophages had better neurological recovery, further supporting a 
protective role of these cells in reduction of stroke injury [38]. F13A1 and STAB1 are 
surface markers of M2 macrophages while ORM1 has been shown to induce the expression 
of CD163, another marker of M2 macrophages [39–41]. Adiponectin primes the transition 
of human monocytes into M2 macrophages representing a key modulator in this 
immunosuppressive response [42]. Another protein induced in this cluster, MBL2, is also 
immunosuppressive and may contribute to M2 transitions as it has been reported to bind 
apoptotic and necrotic cells, facilitating phagocytosis, and in the process directly interacting 
with macrophage receptors to alter cytokine expression, including suppression of pro-
inflammatory cytokines (IL1a, IL1b) and the enhancement of anti-inflammatory cytokines, 
IL10 and IL1ra [43,44], both of which are markers of M2 macrophages [45] and have been 
shown to reduce stroke injury [46,47].
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In addition to immunosuppressive activities, adiponectin has been shown to protect against 
cerebral ischemic injury in the mouse through modulation of endothelial nitric oxide and 
through reduction of oxidative stress [48,49], demonstrating other potential routes to 
neuroprotection. Glucose utilization can be optimized by adiponectin as well as SHBG 
which is associated with glucose metabolism and VAMP5 which is linked to glucose 
transporters [50–52]. Of note, ADIPOQ has been shown to regulate SHBG [53] and was 
grouped with SHBG and MBL2 in an associative network of genes connecting 4 disease 
states (pre-eclampsia, diabetes mellitus, gestational diabetes and obesity) [54].
Along with the proteins associated with M2 macrophages, a number of other proteins that 
are differentially regulated in these animals appear to be involved in reparative responses 
that may be important in recovery from ischemic damage. For example, two proteins, 
MMRN2 and STAB1 are involved in modulating angiogenesis [55,56] and HS6ST1 is 
involved in neuronal axon patterning [57]. In addition, GALNT3 promotes endothelial 
survival [58] and LOXL1 crosslinks collagen to stabilize the extracellular matrix and 
promote vessel wall integrity [59], all of which could contribute to reducing ischemic injury 
and promoting tissue repair. Thus, at least 9 of the 11 proteins with known functions are 
associated with potential reparative responses as anticipated at this late time point.
Interestingly, 6 of the proteins in the neuroprotective cluster are significantly increased over 
the naïve animals as well as showing no induction in the non-protected animals. The 
increase compared to naïve animals may indicate that the protein levels of these in the CSF 
are upregulated in response to the ischemic injury and are not simply representing baseline 
expression levels that were suppressed in the non-protected animals. This may indicate a 
reprogrammed response to the injury that supports a neuroprotective environment, reducing 
the impact of ischemia and promoting recovery. It should be noted that we do not have CSF 
collected from animals that were treated with D192935 without the secondary stroke 
challenge. Thus, we cannot rule out that D192935 treatment alone, 10 days prior to the 
collection of CSF, induced these proteins independent of the stroke event and that in the non-
protected animals where these proteins are not increased a secondary suppression event 
inhibited their expression post stroke.
These studies indicate the biomarker potential of the CSF as a way to monitor therapeutic 
effects in the brain, aiding in the translational development of candidate neuroprotectants. In 
addition, our studies further our knowledge of the potential mechanism of D192935-
preconditioning induced neuroprotection, indicating that immunosuppressive M2 
macrophages may play a role in reparative efforts following ischemic injury. Understanding 
the endogenous mechanisms of preconditioning-induced tissue protection will help in the 
development of prophylactic treatments against ischemic injury for patients undergoing 
high-risk surgical procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Infarct size of the experimental study groups.
D192935 or vehicle was administered via intramuscular injection to male NHPs 3 days prior 
to the onset of surgical occlusion as described in [16]. T2-weighted MR imaging was 
performed on day 2 following reperfusion and infarct size determined as percent of total 
brain. Data presented are a subset of animals, chosen based on infarct size, from previously 
published study [16]. Study groups are shown as CNTL: Vehicle treated; Drug not protected 
(DNP): D192935 treated with large infarcts (Top Box); Drug protected (DP): D192935 
treated with small infarcts (Bottom Box).
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Fig. 2. Principal Component Analysis delineates the study groups.
PCA using the 2125 proteins which had complete data sets for all 19 samples. Shaded 
ellipses denote the different experimental groups.
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Fig. 3. Heatmap of hierarchical clustering of differentially regulated proteins expressed in the 
CNS.
Heatmap of individual protein expression levels (key on right) with hierarchical clustering 
performed using R. Top dendrogram: Individual animals were clustered based on the 
proteomic expression profiles of proteins identified as differentially regulated by ANOVA 
(adjusted p value <0.05). Animal groups and infarct size of individual animals are shown at 
the bottom. A) Point of separation between Minimal Damage and Damage groups. B) Point 
that differentiates DP group from naïve animals. Left dendrogram: Clustering of proteins 
delineates into two distinct cluster groups: Orange) High levels in the Damaged animal 
groups and Green) High levels in the DP Minimal Damage group.
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Fig. 4. Proteins with increased expression in drug protected animals.
Proteins with significant increase in expression in the DP group compared to naïve animals. 
Data are graphed as group means of the final relative expression values (log 2 transformation 
of the ratio of sample abundance to abundance of the pooled reference) +/− SEM. One-way 
ANOVA with Tukey’s multiple comparison post-hoc analysis *p<0.05, **p<0.01 vs naïve; 
#p<0.05, ##p<0.01, ###p<0.001 vs CNTL; ^p<0.05, ^^p<0.01 vs DNP.
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Table 1:
Neuroprotective potential of proteins identified in the Green cluster.
UniProt ID Gene Symbol Human Protein name Potential Neuroprotective Functions Refs.
Q15848 ADIPOQ Adiponectin Primes transition to M2 macrophages, 
reduces oxidative stress, shown to be 
protective in mouse models of 
cerebral ischemia
[42,48, 49]
P00488 F13A1 Coagulation Factor XIII A Chain M2 macrophage marker, increases 
macrophage phagocytosis capability
[39]
O60243 HS6ST1 Heparan sulfate 6-O Sulfotransferase 1 Neuronal axon patterning [57]
Q08397 LOXL1 Lysyl oxidase Like 1 Stabilizes the extracellular matrix [59]
P11226 MBL2 Mannose Binding Lectin Immunosuppressive, binds apoptotic 
and necrotic cells to facilitate 
macrophage phagocytosis and induces 
macrophage secretion of 
immunosuppressive cytokines.
[43,44]
Q9H8L6 MMRN2 Multimerin 2 Angiogenesis [56]
P02763 ORM1/ AGP1 Orosomucoid 1/ Alpha-1-Acid Glycoprotein 1 Immunosuppression, increases CD163 
a M2 macrophage marker
[41]
Q14435 GALNT3 Polypeptide N-Acetylgalactosaminyltransferase 3 Protects endothelial cells [58]
P04278 SHBG Sex hormone-binding globulin Glucose metabolism [50]
Q9NY15 STAB1 Stabilin 1 M2 macrophage marker, increases 
macrophage phagocytosis capability. 
Angiogenesis
[40,55]
O95183 VAMP5 Vesicle Associated Membrane Protein 5 Involved in vesicle transport of the 
glucose transporter, GLUT4
[52]
P04217 A1BG Alpha-1-B Glycoprotein
P01591 JCHAIN Immunoglobulin J Chain
P15814 IGLL1 Immunoglobulin Lambda Like Polypeptide 1
Q9UKX2 MYH2 Myosin Heavy Chain 2
Q5T1S8 NCMAP Non-compact Myelin associated protein
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